WebFeb 23, 2024 · PITTSBORO, N.C., Feb. 23, 2024 /PRNewswire/ -- Propella Therapeutics Inc. (Propella), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), part of the National Institutes of Health, have entered into a Cooperative Research and Development Agreement (CRADA). Under this new … WebFeb 14, 2024 · PITTSBORO, N.C., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company …
Press Release: Propella Therapeutics Announces Licensing …
WebTherapeutics. Headquarters Regions Research Triangle, East Coast, Southern US. Founded Date 2024. Operating Status Active. Legal Name Propella Therapeutics, Inc. Company Type For Profit. Contact Email [email protected]. Phone Number 855.244.4546. Propella Therapeutics creates and develops innovative, best-in-class prescription products that ... WebFeb 20, 2024 · Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer. Read more notive wikitubia
Leading Drug Innovator Reorganizes Into Two Separate Companies
WebMay 19, 2024 · PITTSBORO, N.C., May 19, 2024 /PRNewswire/ -- Propella Therapeutics Inc. (Propella), a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone … WebJun 2, 2024 · FAIRFAX, Va., June 2, 2024 /PRNewswire/ -- Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are … WebFeb 14, 2024 · Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer. Read more notiver hoy columnas